EssilorLuxottica (OTCMKTS:ESLOY) Reaches New 52-Week Low – Here’s What Happened

EssilorLuxottica Unsponsored ADR (OTCMKTS:ESLOY) hit a new 52-week low on Tuesday . The stock traded as low as $110.4050 and last traded at $111.0220, with a volume of 5813 shares. The stock had previously closed at $112.68.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ESLOY shares. Kepler Capital Markets upgraded shares of EssilorLuxottica from a “hold” rating to a “buy” rating in a report on Thursday, January 15th. UBS Group upgraded shares of EssilorLuxottica from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 27th. Citigroup reissued a “buy” rating on shares of EssilorLuxottica in a research report on Thursday, December 11th. HSBC upgraded shares of EssilorLuxottica from a “hold” rating to a “buy” rating in a research note on Wednesday, January 14th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of EssilorLuxottica in a research note on Friday, December 5th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, EssilorLuxottica presently has a consensus rating of “Buy”.

EssilorLuxottica Price Performance

The company has a quick ratio of 0.70, a current ratio of 0.99 and a debt-to-equity ratio of 0.17. The firm has a 50 day moving average price of $139.24 and a 200-day moving average price of $158.50.

EssilorLuxottica Company Profile

EssilorLuxottica SE is a global ophthalmic optics company formed through the 2018 merger of France-based Essilor and Italy-based Luxottica. Headquartered near Paris, the company combines lens manufacturing, frame design and production, brand management and retail operations to provide a vertically integrated offering across the vision care value chain. Its activities span product research and development, manufacturing, wholesale distribution and retailing of spectacles, sunglasses and ophthalmic lenses.

The company’s product portfolio includes prescription and non-prescription lenses, lens coatings and treatments, and an array of eyewear brands and frames.